- Home
- EQBK vs LYEL Comparison
EQBK vs LYEL Comparison
Compare EQBK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQBK | LYEL |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.8M | 745.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EQBK | LYEL |
|---|---|---|
| Price | $44.82 | $30.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $47.80 | $25.00 |
| AVG Volume (30 Days) | 75.3K | ★ 110.2K |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $186,035,000.00 | $41,000.00 |
| Revenue This Year | $15.54 | N/A |
| Revenue Next Year | $37.88 | N/A |
| P/E Ratio | $44.72 | ★ N/A |
| Revenue Growth | ★ 17.93 | N/A |
| 52 Week Low | $34.11 | $7.65 |
| 52 Week High | $48.14 | $45.00 |
Technical Indicators
Market Signals| Indicator | EQBK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 51.49 |
| Support Level | $45.00 | $32.01 |
| Resistance Level | $45.71 | $45.00 |
| Average True Range (ATR) | 1.30 | 3.42 |
| MACD | -0.36 | -0.65 |
| Stochastic Oscillator | 11.98 | 3.20 |
Price Performance
Historical ComparisonAbout EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.